Skip to content
Screener

Vir Biotechnology, Inc. VIR Other revenue — Total revenues

Other product segments

License and collaboration revenue
$238.94M
Grant revenue
$11K-94.0%

Similar metrics at other companies

PROG Holdings logo
PRGOther revenue — Total revenues
$39.4M+134%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
LanzaTech Global, Inc. logo
LNZABiorefining revenue — Total revenues
$6.98M+145%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
Ardelyx logo
ARDXLicensing revenue — Total revenues
$96K+380%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues:
License and collaboration revenue$238,935$(495)$238,894$(565)
Grant revenue11183231,421
Other revenue1,5263,390
Total revenues238,9461,214238,9174,246
Operating expenses:
Cost of revenue1111
Research and development135,28397,509244,205216,154

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s other revenue — total revenues?
Vir Biotechnology, Inc. (VIR) reported other revenue — total revenues of $0 in Q2 2026.
How has Vir Biotechnology, Inc.'s other revenue — total revenues changed year-over-year?
Vir Biotechnology, Inc.'s other revenue — total revenues decreased by 100.0% year-over-year, from $1.53M to $0.
What does other revenue — total revenues mean?
This metric represents the total revenue generated from secondary business activities or non-core product lines that fall outside the company's primary therapeutic focus areas. It captures income streams such as ancillary service contracts, licensing fees, or miscellaneous commercial activities that contribute to the company's overall top-line performance. Monitoring this segment helps investors assess the diversification of revenue sources beyond the core clinical pipeline.

Ask your AI about Vir Biotechnology, Inc.'s other revenue — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude